Span Divergent (524727)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Let me begin with a confession: this is exactly the kind of situation where I would rather watch than act. Span Divergent is a pharmaceutical micro-cap with a market capitalization of just ₹18 Cr. The stock trades at ₹32.30, only half of its ₹63.51 book value. On a Graham basis, that looks superficially cheap. But cheapness must be tested against earning power, not engineering estimates. Here, the latest quarter shows sales of ₹4 Cr and a net loss of ₹1 Cr. Revenue has grown over 100%, but profits have collapsed by 535.94%. That is not growth; that is spending money to buy sales. ROCE of -186.79% is a brutal measure of capital efficiency, and an ROE of 2.31% is nowhere near enough to justify owning such a small, volatile business. The Piotroski score of 3/9 reinforces my caution. There is no dividend to cushion the wait, promoter holding is not disclosed, and P/E of 0.00 tells me the market cannot put a multiple on earnings that do not exist. Benjamin Graham would want liquid assets, strong current ratio, and positive earnings. This business has none of those visible. A discount to book value can be a value trap if the book is being burned by losses. The 52-week range of ₹20.81 to ₹36.67 shows this is a low-priced speculative stock. I would need evidence of positive cash flow, sustainable margins, and trustworthy management. Until then, I do not see an investment; I see a possible cigar butt with one puff left. In Mr. Market's complex arena, it is okay to say 'I don't understand enough.' This belongs in the too-hard pile.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer